UK Markets close in 6 hrs 45 mins
  • FTSE 100

    6,379.03
    +112.84 (+1.80%)
     
  • FTSE 250

    19,571.47
    +235.15 (+1.22%)
     
  • AIM

    1,060.21
    +9.67 (+0.92%)
     
  • GBP/EUR

    1.1153
    -0.0015 (-0.14%)
     
  • GBP/USD

    1.3360
    +0.0028 (+0.2111%)
     
  • BTC-GBP

    14,566.17
    +20.26 (+0.14%)
     
  • CMC Crypto 200

    382.82
    +18.22 (+5.00%)
     
  • S&P 500

    3,621.63
    -16.72 (-0.46%)
     
  • DOW

    29,638.64
    -271.73 (-0.91%)
     
  • CRUDE OIL

    45.54
    +0.20 (+0.44%)
     
  • GOLD FUTURES

    1,796.10
    +15.20 (+0.85%)
     
  • NIKKEI 225

    26,787.54
    +353.92 (+1.34%)
     
  • HANG SENG

    26,567.68
    +226.19 (+0.86%)
     
  • DAX

    13,426.39
    +135.23 (+1.02%)
     
  • CAC 40

    5,577.34
    +58.79 (+1.07%)
     

Correction: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic A/S
·2-min read

COPENHAGEN, Denmark, November 13, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) publishes corrected information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Anu Helena Kerns

2.

Reason for the notification

a)

Position/status

Executive Vice President People & Organization of Bavarian Nordic A/S

b)

Initial notification/Amendment

Amendment to notification of November 11, 2020. The volume of granted warrants has been adjusted.

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bavarian Nordic A/S

b)

LEI

2138006JCDVYIN6INP51

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument


Identification code

Warrants


DK0015998017

b)

Nature of the transaction

Grant

c)

Price(s) and volume(s)

Price(s)

Volume(s)

DKK 0.00

38,756

d)

Aggregated information



38,756
DKK 0.00

e)

Date of the transaction

2020-11-11

f)

Place of the transaction

Outside a trading venue

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 49 / 2020

Attachment